

consistent with the intended use of funds.

#### 7. Human Subjects (Not Scored)

If human subjects will be involved, the extent to which the applicant describes how will they be protected, i.e., describe the review process which will govern their participation.

#### H. Other Requirements

Technical Reporting Requirements  
Provide CDC with original plus two copies of—

1. Annual progress reports;
  2. Financial status report, no more than 90 days after the end of the budget period; and
  3. Final financial status and performance reports, no more than 90 days after the end of the project period.
- Send all reports to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I (included in the application package).

- AR-9 Paperwork Reduction Act Requirements
- AR-10 Smoke-Free Workplace Requirements
- AR-11 Healthy People 2000
- AR-12 Lobbying Restrictions
- AR-20 Conference Grants

#### I. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under sections 20(a) and 22(e) of the Occupational Safety and Health Act of 1970 [29 U.S.C. 669(a) and 671(e) (7)]. The Catalog of Federal Domestic Assistance number is 93.283.

#### J. Where To Obtain Additional Information

The application kit for 99147 can also be downloaded via the CDC home page on the Internet: <http://www.cdc.gov>

Please refer to Program Announcement 99147 when you request information. To receive additional written information and to request an application kit, call 1-888-GRANTS4 (1-888-6874). You will be asked to leave your name, address, and phone number and will need to refer to NIOSH Announcement 99147. You will receive a complete program description, information on application procedures, and application forms. CDC will not send application kits by facsimile or express mail.

If you have any questions after reviewing the contents of all the documents, business management technical assistance may be obtained by

contacting: Sheryl Heard, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Announcement 99147, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, GA 30341, telephone (770) 488-2723, E-mail address: slh3@cdc.gov.

For program technical assistance, contact Gregory Wagner, M.D., National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC) Division of Respiratory Disease Studies, 1095 Willowdale Road, P-B121, Morgantown, West Virginia 26505-2888, Telephone (304) 285-5749, e-mail grw3@cdc.gov.

Dated: May 27, 1999.

**Diane D. Porter,**

*Acting Director, National Institute for Occupational Safety and Health Centers for Disease Control and Prevention (CDC).*

[FR Doc. 99-14002 Filed 6-2-99; 8:45 am]

BILLING CODE 4163-19-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### Centers for Disease Control and Prevention

##### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Prevention Research Initiative—Health Communications Research Grants

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

*Name:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Prevention Research Initiative—Health Communications Research Grants, Program Announcement #99107, meeting.

*Times and Dates:* 8:30 a.m.–9:15 a.m., July 21, 1999 (Open). 9:15 a.m.–4:30 p.m., July 21, 1999 (Closed). 8:30 a.m.–4:30 p.m., July 22, 1999 (Closed). 8:30 a.m.–4:30 p.m., July 23, 1999 (Closed).

*Place:* Atlanta Marriott North Central Hotel, 2100 Century Boulevard N.E., Atlanta, Georgia 30345.

*Status:* Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552(b)(4) and (6), Title 5 U.S.C., and the Determination of the Acting Associate Director for Management and Operations, CDC, pursuant to Public Law 92-463.

*Matters to be discussed:* The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement #99107.

*Contact person for more information:* Alan Janssen, M.S.P.H., Office of Communication, CDC, 1600 Clifton Rd., m/s D24, Atlanta, Georgia 30043. Telephone 404/639-2916, fax 404/639-3942, e-mail axj3@cdc.gov.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: May 27, 1999.

**John C. Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC.*

[FR Doc. 99-14003 Filed 6-2-99; 8:45 am]

BILLING CODE 4163-18-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### Centers for Disease Control and Prevention

##### Genetics of Congenital Hearing Impairment; Workshop

The Division of Child Development, Disability, and Health (DCDDH) in the National Center for Environmental Health (NCEH) at the Centers for Disease Control and Prevention (CDC) announces the following workshop.

*Name:* A workshop entitled, The Genetics of Congenital Hearing Impairment, jointly sponsored by the Developmental Disabilities Branch, DCDDH, NCEH, CDC and Gallaudet University.

*Time and Date:* 8 a.m.–5 p.m., June 7, 1999.

*Place:* The Centers for Disease Control and Prevention, Chamblee Facility, Room 2201/2202, Building 102, 4770 Buford Highway, NE, Atlanta, Georgia 30341.

*Status:* Open for participation by anyone with an interest in Genetics of Congenital Hearing Impairment, limited only by the space available. Persons wishing to participate must e-mail their request to [higen@cdc.gov](mailto:higen@cdc.gov) and indicate if they will attend or if they will participate through a conference call on Eastern time. The conference telephone bridge number for Federal participants is 404/639-4100. The conference telephone bridge number for non-Federal participants is 800/713-1971. The Conference Code number is 486602. For security and confidentiality purposes, participants will not be connected to a conference call without a valid conference code number. The conference name is Genetics of Congenital Hearing. If you have a problem during your conference, you may press \*0 at anytime to signal the attendant. If you have questions, about the technical operations of the teleconference equipment please call 404/639-7550. Each participant will have the responsibility to call in to connect to the conference call.

*Matters To Be Discussed:* The objectives for the workshop are: (1) To discuss the public

health role and significance in population-based research of the genetics of congenital hearing impairment, (2) to develop strategies for population-based study of genetics of congenital hearing impairment, (3) to exchange ideas on the ethical and policy implications of public health research in the genetics of congenital hearing impairment, (4) to build partnerships between federal, state, academic, and private organizations to address activities for population genetics in congenital hearing impairment.

The workshop will provide a forum to discuss the strengths and limitations of several very specific study approaches that could be used to document the needed population-based research. We are particularly interested in strategies that involve collaboration with state-based Early Hearing Detection and Intervention (EHDI) programs. We are particularly interested in the perspectives of genetic ethicist; the deaf and hard-of-hearing communities; and state and local participants in universal newborn hearing detection and intervention programs.

**Contact Persons for More Information:** Kim Van Naarden, M.P.H., telephone 770/488-7184, or Marilyn Deal, telephone 770/488-7695, Division of Child Development, Disability, and Health, NCEH, CDC, 4770

Buford Highway, NE, Mailstop F-15, Atlanta, Georgia 30341. Fax 770/488-7361.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: May 26, 1999.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 99-13981 Filed 6-2-99; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Proposed Information Collection Activity; Comment Request

##### *Proposed Project*

*Title:* State Plan for Foster Care and Adoption Assistance—Title IV-E.

*OMB No.:* 0980-0141.

*Description:* A State plan for foster care and adoption assistance is required by section 471 of the Social Security Act from any State wishing to claim Federal financial participation for foster care and adoption assistance. States may use a preprinted format or may develop their own format which meets the requirements of the law. The plan is submitted only once and amended as necessary. Our experience is that a State will amend a plan once every 4 years; approximately 12 per year.

*Respondents:* State, Local or Tribal Govt.

#### ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
State Plan for Foster Care and Adoption Assistance .....	12	1	15	180

#### *Estimated Total Annual Burden Hours:* 180.

In compliance with the requirements of Section 3506(c)(2)(A) the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above.

Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the

collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: May 27, 1999.

**Bob Sargis,**

*Reports Clearance Officer.*

[FR Doc. 99-13984 Filed 6-2-99; 8:45 am]

**BILLING CODE 4184-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 99C-1455]

#### **Genzyme Surgical Products Corp.; Filing of Color Additive Petition**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Genzyme Surgical Products Corp. has filed a petition proposing that the

color additive regulations be amended to provide for the safe use of D&C Violet No. 2 as a color additive in absorbable sutures prepared from homopolymers of glycolide for general surgery. The petitioner also proposes that the nomenclature polyglactin 910 (glycolic-lactic acid polyester) be revised to the generic nomenclature-copolymers of 90 percent glycolide and 10 percent L-lactide.

**FOR FURTHER INFORMATION CONTACT:** Ellen M. Waldron, Center for Food Safety and Applied Nutrition (HFS-217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3089.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 721(d)(1) (21 U.S.C. 379e(d)(1)), notice is given that a color additive petition (CAP 9C0266) has been filed by Genzyme Surgical Products Corp., 600 Airport Rd., Fall River, MA 02720. The petition proposes to amend the color additive regulations in § 74.3602 *D&C Violet No. 2* (21 CFR 74.3602) to provide for the safe use of D&C Violet No. 2 as a color additive in absorbable sutures prepared from homopolymers of glycolide for general surgery. The